Literature DB >> 27518054

President's message: Ensuring appropriate ordering of tests and eliminating inconclusive test results.

Myron C Gerson.   

Abstract

Year:  2006        PMID： 27518054     DOI： 10.1016/j.nuclcard.2006.05.010

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  10 in total

1.  Diagnosis of coronary artery disease by exercise thallium-201 tomography in patients with a right ventricular pacemaker.

Authors:  N M Lakkis; Z X He; M S Verani
Journal:  J Am Coll Cardiol       Date:  1997-05       Impact factor: 24.094

Review 2.  ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association.

Authors:  Ralph G Brindis; Pamela S Douglas; Robert C Hendel; Eric D Peterson; Michael J Wolk; Joseph M Allen; Manesh R Patel; Ira E Raskin; Robert C Hendel; Timothy M Bateman; Manuel D Cerqueira; Raymond J Gibbons; Linda D Gillam; John A Gillespie; Robert C Hendel; Ami E Iskandrian; Scott D Jerome; Harlan M Krumholz; Joseph V Messer; John A Spertus; Stephen A Stowers
Journal:  J Am Coll Cardiol       Date:  2005-10-18       Impact factor: 24.094

3.  Dobutamine technetium-99m tetrofosmin SPECT imaging for the diagnosis of coronary artery disease in patients with limited exercise capacity.

Authors:  A Elhendy; F B Sozzi; R Valkema; R T van Domburg; J J Bax; J R Roelandt
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

Review 4.  Dobutamine stress myocardial perfusion imaging.

Authors:  M L Geleijnse; A Elhendy; P M Fioretti; J R Roelandt
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

5.  Effects of dobutamine stress on myocardial blood flow, 99mTc sestamibi uptake, and systolic wall thickening in the presence of coronary artery stenoses: implications for dobutamine stress testing.

Authors:  D A Calnon; D K Glover; G A Beller; G Vanzetto; W H Smith; D D Watson; M Ruiz
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

6.  Limitations of dobutamine for enhancing flow heterogeneity in the presence of single coronary stenosis: implications for technetium-99m-sestamibi imaging.

Authors:  J C Wu; J J Yun; E N Heller; D P Dione; P DeMan; Y H Liu; B L Zaret; F J Wackers; A J Sinusas
Journal:  J Nucl Med       Date:  1998-03       Impact factor: 10.057

7.  Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs.

Authors:  T Sharir; B Rabinowitz; S Livschitz; I Moalem; J Baron; E Kaplinsky; P Chouraqui
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

8.  Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging.

Authors:  Raymond Taillefer; Alan W Ahlberg; Yasmin Masood; C Michael White; Isabella Lamargese; Jeffrey F Mather; Carol C McGill; Gary V Heller
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

9.  Risk stratification with electrocardiographic-gated dobutamine stress technetium-99m sestamibi single-photon emission tomographic imaging: value of heart rate response and assessment of left ventricular function.

Authors:  Sachin M Navare; Deborah Katten; Lynne L Johnson; Jeffery F Mather; Michael S Fowler; Alan W Ahlberg; Nicholas Miele; Gary V Heller
Journal:  J Am Coll Cardiol       Date:  2006-01-30       Impact factor: 24.094

10.  Adenosine thallium-201 is superior to exercise thallium-201 for detecting coronary artery disease in patients with left bundle branch block.

Authors:  J H O'Keefe; T M Bateman; C S Barnhart
Journal:  J Am Coll Cardiol       Date:  1993-05       Impact factor: 24.094
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.